The FDA is convening a panel of its outside advisers over two days on 11-12 June to help the agency flesh out whether to require cardiovascular outcomes trials (CVOTs) for all, only specific or none of the peripherally active mu opioid receptor antagonists being developed to treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
FDA seeks advice on opioid-induced constipation drugs’ risks
The FDA is convening a panel of its outside advisers over two days on 11-12 June to help the agency flesh out whether to require cardiovascular outcomes trials (CVOTs) for all, only specific or none of the peripherally active mu opioid receptor antagonists being developed to treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.